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Table. CMX001-201 Study. Selected Baseline Characteristics and Efficacy/Safety Summary Data (blinded data, as of 30 September
2011)
Cohort 40mg/placebo QW 100mg/placebo QW 200mg/placebo (QW) 200mg/placebo BIW 100mg/placebo BIW
Patients enrolled, N 40 39 53 40 67
Evaluable patients, N 33 37 53 40 67
Baseline characteristics Percent of Evaluable Patients
Peripheral Stem-Cell recipients 85% 89% 72% 75% 87%
Bone Marrow Recipients 6% 3% 19% 20% 10%
Umbilical Cord-Blood Recipients 9% 8% 9% 5% 3%
ATG Administration during Conditioning 15% 14% 8% 15% 18%
Acute GVHD at baseline 18% 16% 11% 17% 9%
CMV PCR negative before dosing 70% 84% 76% 78% 84%
Completed treatment 36% 49% 43% 28% 57%
Efficacy Results
CMV Events to End of Treatment 42% 32% 19% 20% 18%
CMV DNAemia >1000 copies/mL 45% 27% 21% 18% 12%
Serious Adverse Events (SAE)
Patients with SAEs Leading to Discontinuation 21% 12% 9% 25% 6%
S204 CIBMTR Best Abstract Awards for Clinical ResearchResults: FromDec 2009 to Jun 2011, 239 subjects were enrolled into
the study. As of Oct 2011, all subjects had completed treatment and
final safety follow-up visits were underway. Blinded efficacy results
demonstrated a decrease of appearance or progression ofCMV infec-
tion or disease by day 100 post-SCT in subjects enrolled in higher
dose cohorts (see table). Dose-limiting diarrhea, often reported in
conjunction with GVHD, occurred in subjects treated in the highest
dose cohort (200mg BIW). Changes in renal and graft function were
similar across all cohorts during treatment and follow up. Final, un-
blinded safety and efficacy results of the study will be presented.
Conclusions: In this first Phase 2 trial of CMX001 ever conducted,
a reduction in new or progressive CMV infection occurred in alloge-
neic SCT patient cohorts receiving higher doses of CMX001
($200mg weekly). An increased incidence of diarrhea occurred in
patients receiving the highest dose of CMX001 (200mg BIW).
CMX001 has potential as a prophylactic antiviral agent in this pop-
ulation.
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We examined whether overlap subtype of chronic GVHD was
associated with different prognosis, functional limitations, or pa-
tient reported outcomes compared to ‘‘classic’’ chronic GVHD.
Prospective data were collected from 427 patients from nine cen-
ters in an observational cohort study conducted by the ChronicGVHD Consortium. Patients were classified as overlap (n 5 352)
or classic chronic GVHD (n 5 75) based on organ involvement.
Among 352 overlap subjects, skin erythema or maculopapular
rash was present in 189 (54%), GI involvement in 129 (37%),
and liver involvement in 216 (62%); 198 (56%) met criteria with
acute features in only one organ, 126 (36%) with acute features
in two organs, and 28 (8%) with acute features in all three organs.
Overlap patients were more likely to be incident cases (59% vs
35%, p\.001), to have a shorter median time from transplant to
enrollment (11.9 months vs. 19.8 months, p 5 0.01), and to have
lower platelet count at chronic GVHD onset (p\ 0.001). Those
with overlap had significantly higher functional impairment by 2
minute walk test (p\0.001), higher symptom burden (Lee Chronic
GVHD Symptoms Scale) and lower Human Activity Profile scores
(p\0.001). Quality of life was similar, except overlap had worse SF-
36 social functioning. The median follow-up time after enrollment
for overlap patients was 17.1 months, and 19.0 months for classic
chronic GVHD patients. Two year OS was 77% and 94%, and
two year NRM was 20% and 3% for overlap and classic chronic
GVHD patients, respectively. Multivariable analyses in which over-
lap and classic were treated as time-varying covariates demon-
strated that overlap was associated with worse overall survival
(HR 2.1, 95% CI 1.1 – 4.7; p 5 0.03) and higher non-relapse mor-
tality (HR 2.8, 95% CI 1.2 – 8.3; p 5 0.02) than classic chronic
GVHD. Among other considered covariates in the OS analysis,
platelet count \ 100K (HR 3.4, 95% CI 1.9 – 6, p \ 0.001),
KPS \ 80 (HR 2.4, 95% CI 1.4 – 4.1, p 5 0.002), and severe
NIH global severity score (HR 5.1, 95% CI 1.5 – 32.1, p 5
0.03) were associated with OS. In the analysis of NRM, platelet
\ 100K (HR 3.1, 95% CI 1.6 – 5.9, p\ 0.001), and KPS\ 80
(HR 2.2, 95% CI 1.2 – 4.2, p 5 0.01) were associated with
NRM. These findings suggest that the presence of acute features
in patients with chronic GVHD is a marker for adverse prognosis,
greater functional impairment, and higher symptom burden. Fur-
ther study is needed to define optimal therapy for these patients.
